Tendinopathy Treatment Algorithm by Line of Therapy

What Is Tendinopathy and How Is It Diagnosed?

Tendinopathy describes a failed healing response in tendons producing pain, swelling, and reduced function. It is not primarily an inflammatory condition. Histology consistently shows collagen disorganisation, neovascularisation, and the near-absence of inflammatory cells, a pattern called tendinosis.

Clinical Presentation

The diagnosis is clinical in most cases. Patients report localised tendon pain that is worse with loading, eases briefly with warm-up, and returns after activity. The Royal London Hospital Test (arc-sign) is useful for mid-portion Achilles tendinopathy. Victorian Institute of Sport Assessment (VISA) scoring tools quantify severity across Achilles (VISA-A), patellar (VISA-P), and shoulder (VISA-S) regions and are recommended by the British Journal of Sports Medicine (BJSM) consensus for outcome tracking [1].

Symptoms must be present for at least 3 months before a degenerative diagnosis is appropriate. Acute paratenonitis or partial tears present differently and alter management.

Imaging Confirmation

Imaging is not required to start treatment but is indicated when the diagnosis is uncertain, when a partial or full-thickness tear is suspected, or when invasive procedures are planned. Diagnostic ultrasound identifies intratendinous hypoechoic regions and neovascularisation with Doppler. MRI provides superior soft-tissue detail for rotator cuff and patellar pathology. A 2020 systematic review in the British Journal of Sports Medicine confirmed that ultrasound findings do not reliably predict clinical outcomes, so imaging should inform, not override, the clinical picture [2].

First-Line Treatment: Load Management and Exercise Therapy

Exercise-based loading is the single most evidence-supported intervention for all tendinopathy locations. The goal is to progressively stress the tendon to stimulate collagen remodelling without provoking a pain flare above 4 out of 10 on a numeric pain scale.

Eccentric Exercise Protocol

Alfredson and colleagues published the landmark eccentric protocol for mid-portion Achilles tendinopathy in 1998. Over 12 weeks, twice daily eccentric calf raises produced an 82% satisfactory outcome rate (N=15 eccentric, N=15 controls) versus 0% in the control group, leading to return to running in all eccentric responders [3]. The protocol involves 3 sets of 15 repetitions twice daily, seven days per week, on a declined board or stair edge.

Eccentric exercise is now a core recommendation in the 2018 British Journal of Sports Medicine consensus on Achilles tendinopathy [1].

Heavy Slow-Resistance (HSR) Training

HSR uses slower tempo and heavier loads than the Alfredson protocol. A randomised trial by Beyer et al. (N=58, 2015) found HSR produced outcomes equivalent to Alfredson eccentric loading at 12 weeks for pain and function, with higher patient satisfaction (P<0.001) [4]. HSR may be more tolerable in patients who cannot perform the isolated eccentric movement pattern and is increasingly preferred in clinical practice for patellar and rotator cuff tendinopathy.

Load Monitoring and Return-to-Sport

A pain monitoring model developed by Silbernagel et al. Allows patients to continue sport if tendon pain stays at or below 4 out of 10 during activity and returns to baseline within 24 hours. This model produced no adverse tendon outcomes over 12 weeks in a cohort of 34 athletes [5]. Structured return-to-running programmes typically span 8 to 12 weeks after the pain settles during strength work.

Second-Line Treatment: Adjunct Therapies

When 12 weeks of supervised exercise has not produced adequate pain relief or functional gains, the following adjuncts can be layered in. None replace loading. They are tools to reduce pain enough to allow continued exercise participation.

Extracorporeal Shockwave Therapy (ESWT)

ESWT delivers acoustic pressure waves to the tendon, stimulating collagen synthesis and inhibiting nociceptive fibres. A 2017 meta-analysis in the American Journal of Sports Medicine (17 RCTs, N=1,144) found ESWT significantly superior to sham for Achilles tendinopathy pain at 12 weeks (standardised mean difference 0.61, 95% CI 0.38 to 0.84) [6]. Standard protocols use 3 to 5 sessions at weekly intervals, 2,000 impulses per session at 0.1 to 0.4 mJ/mm².

ESWT is generally well-tolerated. Transient local pain and redness occur in roughly 10 to 20% of patients. It is contraindicated directly over open growth plates, implanted pacemakers, or sites of known malignancy.

Corticosteroid Injections

Corticosteroid injection provides reliable short-term pain relief but carries a clinically meaningful risk of tendon rupture with repeated use. A 2010 Cochrane review (N=381, 13 trials) found corticosteroid superior to placebo for lateral epicondylitis at 4 to 6 weeks, but this benefit reversed by 26 weeks and the placebo group had better long-term outcomes [7]. Current BJSM consensus guidance states that corticosteroid should not be the primary treatment for tendinopathy and no more than two injections should be given in any tendon. Intratendinous injection should be avoided; peritendinous delivery is safer.

Glyceryl Trinitrate (GTN) Patches

Topical GTN delivers nitric oxide to the tendon, promoting collagen synthesis. A double-blind RCT by Paoloni et al. (N=86) found 0.2 mg per hour GTN patches reduced pain at rest and during activity for chronic Achilles tendinopathy at 6 months versus placebo (P<0.013) [8]. Headache is the main adverse effect, occurring in roughly 30% of users. GTN is applied over the tendon pain point once daily for 24 weeks.

Third-Line Treatment: Injection-Based and Biological Therapies

Patients who fail 12 to 24 weeks of combined exercise therapy and adjunct treatment enter the refractory category. Third-line options have more variable evidence bases and several are used off-label.

Platelet-Rich Plasma (PRP)

PRP concentrates autologous growth factors including PDGF, TGF-beta, and VEGF to stimulate tendon healing. Evidence quality is mixed and highly dependent on preparation method and injection technique.

A 2021 Cochrane review of PRP for lateral epicondylitis (14 trials, N=931) concluded there is low-certainty evidence that a single PRP injection reduces pain more than placebo at 3 months (mean difference approximately 10 points on a 100-point VAS), with the clinical significance uncertain [9]. A 2022 NEJM-published RCT by Puzzitiello et al. (N=100) comparing PRP to saline for rotator cuff tendinopathy found no significant difference in ASES scores at 12 months (P=0.45) [10].

PRP is not FDA-approved for tendinopathy but is used as a 361 HCT/P product under a practitioner-use exemption. Preparation variables, platelet concentration, leukocyte content, and activation method differ significantly across commercial systems. Standardisation remains an active research area.

Sclerosing Polidocanol Injection

Neovascularisation is a marker of chronic tendinopathy. Polidocanol (a sclerosant) injected under Doppler ultrasound guidance targets these neovessels and the sensory nerve fibres that accompany them. A randomised trial by Alfredson and Ohberg (N=20) found 80% of patients treated with polidocanol reported <20 out of 100 VAS pain scores at 6 months versus 20% of controls [11]. The technique requires operator expertise and ultrasound guidance. It is used primarily for Achilles and patellar tendinopathy.

BPC-157 (Body Protection Compound-157)

BPC-157 is a synthetic pentadecapeptide derived from a gastric protein. It is not FDA-approved for any indication and is classified by the FDA as a compound that cannot be used in compounding under the Federal Food, Drug, and Cosmetic Act as of 2023 [12]. Despite the regulatory status, it is widely available through compounding pharmacies and discussed in the tendinopathy literature.

Preclinical data from rodent models consistently show accelerated tendon-to-bone healing and reduced post-injury inflammation. A 2019 study in the Journal of Orthopaedic Research reported that BPC-157 increased collagen organisation and biomechanical strength in Achilles transection models at 4 weeks [13]. No peer-reviewed human RCT data for tendinopathy exist at the time of publication. Any use in clinical practice carries regulatory and safety risks the prescribing clinician must discuss explicitly with the patient.

The table below summarises HealthRX's clinical decision framework for sequencing these third-line options based on tendon location, available imaging, and prior treatment history.

| Tendon Location | Preferred Third-Line Option | Imaging Requirement | Notes | |---|---|---|---| | Mid-portion Achilles | PRP or polidocanol sclerosant | Doppler ultrasound | Polidocanol if neovascularisation confirmed | | Insertional Achilles | PRP | MRI to exclude calcific enthesopathy | Calcific disease may require ESWT intensification instead | | Patellar | PRP | Ultrasound | HSR must continue through recovery | | Lateral epicondyle | PRP | Clinical diagnosis sufficient | One RCT cycle; reassess at 12 weeks | | Rotator cuff (non-tear) | PRP | MRI to exclude full-thickness tear | Full-thickness tear changes management to surgical pathway |

Surgical Referral: When Conservative Care Has Failed

Surgical intervention is appropriate after 6 to 12 months of structured, documented conservative management that includes at least 12 weeks of supervised loading and at least one second-line or third-line adjunct. Surgical options include:

• Open or endoscopic tendon debridement to remove degenerative tissue
• Longitudinal tenotomy to stimulate healing response
• Tendon transfer for severe cases with significant structural failure

Outcomes data for surgical debridement of Achilles tendinopathy show 75 to 85% satisfaction rates at 2 years in observational series, though high-quality RCTs comparing surgery to continued conservative care are scarce. A 2011 systematic review by Alfredson in the British Journal of Sports Medicine found that 40% of patients who failed conservative care went on to have successful surgery, but 15% had persistent pain or complications [14].

The decision to operate must account for patient age, activity demands, comorbidities (particularly diabetes, which impairs tendon healing), and the structural integrity of the tendon on imaging.

Special Populations and Comorbidity Considerations

Diabetes and Metabolic Syndrome

Hyperglycaemia impairs collagen synthesis and cross-linking, increasing tendinopathy risk by 3.8-fold in people with type 2 diabetes compared to normoglycaemic controls, per a 2016 meta-analysis in Diabetes Care (6 studies, N=229,000) [15]. Glucose optimisation is part of the treatment plan, not just background management. The American Diabetes Association Standards of Care 2024 recommend HbA1c targets below 7% to reduce microvascular complications, a category that includes tendon vascularity impairment [16].

Fluoroquinolone-Associated Tendinopathy

Ciprofloxacin and other fluoroquinolones carry an FDA black-box warning for tendon rupture risk [17]. Patients presenting with Achilles tendinopathy within 6 months of fluoroquinolone use should be evaluated for partial tear on MRI before beginning aggressive loading, as standard eccentric protocols may precipitate complete rupture in structurally compromised tissue.

Anabolic Steroid and GLP-1 Related Considerations

Exogenous anabolic androgens stiffen tendons and may increase injury risk during rapid strength gains. GLP-1 receptor agonists, including semaglutide, produce rapid weight loss that reduces compressive load on lower-limb tendons. Early data suggest this load reduction may reduce insertional Achilles and patellar tendon pain in patients with obesity-related tendinopathy, though prospective trial data are not yet available.

Monitoring Outcomes Across the Treatment Algorithm

Structured outcome monitoring prevents patients from staying on ineffective treatments too long. The following framework reflects current best practice:

VISA Scoring at Baseline, 6 Weeks, and 12 Weeks

VISA-A scores below 40 indicate severe impairment. A clinically meaningful improvement is defined as a 10-point or greater increase. Patients who have not improved by at least 10 VISA points after 12 weeks of structured first-line care should move to second-line adjuncts without delay.

Pain Monitoring During Loading

The numeric pain scale threshold of 4 out of 10 is both a safety marker and a rehabilitation guide. Persistent pain above 5 out of 10 for more than 24 hours after a session signals overload and requires load reduction of approximately 20 to 30% for the following week.

Imaging Reassessment

Repeat imaging is appropriate before any invasive procedure and at the point of surgical referral consideration. Tendon thickness on ultrasound and intratendinous signal on MRI correlate imperfectly with symptoms but guide injection targeting.